Progentix Orthobiology B.V. Closes Series A Financing Round

BILTHOVEN, The Netherlands, January 22 /PRNewswire/ -- Progentix
Orthobiology B.V. announced today the closure of its Series A financing
Round. The round was led by BioGeneration Ventures.
Progentix Orthobiology B.V. was established in 2007 and develops a unique
suite of osteoinductive material products for clinical application in bone
regenerative surgery. Progentix bone graft material is based on surface
structured ceramic biomaterial scaffolds that have the ability to attract
growth factors and stems cells after implantation, which results in the
induction of bone growth. These materials are not only superior to currently
available synthetic ceramic bone grafts, but based on their bone healing and
regeneration potential also directly compete with the gold standard of
autologous bone, and the growth factors that are being used today and those
under development. The Series A financing round will support further
technology validation and the generation of clinical proof of principle.
Dr. Joost de Bruijn, CEO of Progentix Orthobiology said: "We are
extremely pleased with the support of BioGeneration Ventures. This financing
round will allow us to continue building value and lay the groundwork for the
launch of our first products in the near future."
"We strongly believe in the high quality of the Progentix Orthobiology
technology," says Edward van Wezel M.Sc., managing partner at BioGeneration
Ventures BV. "This novel technology platform will address a real medical need
in the area of bone grafts. The scientific team has an excellent track record
in the development of biomaterials and tissue engineering." Dr. Clemens van
Blitterswijk, professor in Tissue Regeneration at the University of Twente
and former CEO of IsoTis N.V., and Edward van Wezel will join the board of
directors of Progentix Orthobiology.
About Biogeneration Ventures BV
BioGeneration Ventures invests in Dutch Life Sciences companies. The team
of BioGeneration is specialized in the evaluation of new technologies and in
the management of start-up companies. BioGeneration Ventures was co-founded
by the Netherlands Genomics Initiative (NGI), NWO, the holding of the
University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates
with Forbion Capital Partners (http://www.forbion.com).
Contact:

Progentix Orthobiology B.V.
Prof. Dr. Joost de Bruijn
T: +31-30-2295234
E: info@progentix.com

W: http://www.progentix.com

BioGeneration Ventures B.V.
Edward van Wezel
T: +31-35-6993011
E: info@biogenerationventures.com

W: http://www.biogenerationventures.com

SOURCE Progentix Orthobiology

Contact: Progentix Orthobiology B.V., Prof. Dr. Joost de Bruijn, T:
+31-30-2295234, E: info@progentix.com; BioGeneration Ventures B.V., Edward van
Wezel, T: +31-35-6993011, E: info@biogenerationventures.com